Healius Limited provides various services and facilities to general practitioners, dentists, physiotherapists, specialists, and other healthcare professionals in Australia. It operates through three segments: Pathology, Medical Centres, and Imaging. The company offers diagnostic imaging services, such as X-ray, ultrasound, computerized tomography, mammography, MRI, positron emission tomography, interventional radiology, and nuclear medicine services; and medical laboratory and pathology services. It also operates medical centers that provide nursing support, pathology, radiology, dental, physiotherapy, and allied health services; and IVF services, eye and skin specialists, skin cancer checks, and consultant specialist doctors. The company operates 70 medical centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in St Leonards, Australia.
Industry, Sector and Symbol
Industry Medical Care
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 2 9432 9400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.81 billion
Profitability
Miscellaneous
Employees12,000
Next Earnings DateN/A
OptionableNot Optionable
Healius (ASX:HLS) Frequently Asked Questions
What is Healius' stock symbol?
Healius trades on the ASX under the ticker symbol "HLS."
How often does Healius pay dividends? What is the dividend yield for Healius?
Healius declared a Final dividend on Tuesday, August 20th. Shareholders of record on Friday, September 27th will be given a dividend of 0.034 per share on Friday, September 27th. This represents a yield of 1.13%. The ex-dividend date of this dividend is Thursday, August 29th. View Healius' Dividend History.
Has Healius been receiving favorable news coverage?
Headlines about HLS stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Healius earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Healius.
Who are some of Healius' key competitors?
Some companies that are related to Healius include NMC Health (NMC), Mediclinic International (MDC), Rhoen Klinikum (RHK), Spire Healthcare Group (SPI), CareTech (CTH), Virtus Health (VRT), Pacific Smiles Group (PSQ), Georgia Healthcare Group (GHG), Assure (IOM), CENTRIC HEALTH (CHH), Konekt (KKT), Totally (TLY), Brain Resource (BRC), Nobilis Health (HLTH) and Venn Life Sciences (VENN).
Who are Healius' key executives?
Healius' management team includes the folowing people:
- Dr. Malcolm W. Parmenter, MD, CEO & Director (Age 64)
- Mr. Malcolm Robert Ashcroft, Chief Financial Officer (Age 45)
- Ms. Maxine Jaquet, Chief Exec. of Health & Co
- Mr. Dean Lewsam, Chief Exec. of Imaging
- Mr. Wesley Lawrence, Chief Exec. of Pathology
What is Healius' stock price today?
One share of HLS stock can currently be purchased for approximately A$3.07.
How big of a company is Healius?
What is Healius' official website?
How can I contact Healius?
The company can be reached via phone at 61 2 9432 9400.
MarketBeat Community Rating for Healius (ASX HLS)
MarketBeat's community ratings are surveys of what our community members think about Healius and other stocks. Vote "Outperform" if you believe HLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
